Analysis by Optimly for Optimly AI Visibility, in the Optimly AI Brand Index. This Business Profile tracks the Brand Authority Index and supporting AI visibility evidence. Last analyzed August 30, 2026.
Vertex is RNA and DNA Targeted Therapies.
Vertex's core products are CRISPR-based therapy (Casgevy) for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT); CFTR modulator therapies for Cystic Fibrosis; investigational treatments for IgA nephropathy and type 1 diabetes (T1D)..
Vertex uses Not specified in the provided text, but typical for pharmaceutical products (value-based, prescription-based)..
Vertex serves Patients with serious diseases such as cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, IgA nephropathy, type 1 diabetes, and APOL1-mediated kidney disease..
Vertex Commitment to scientific innovation to create transformative medicines, pioneering genetic treatments (e.g., first-and-only genetic treatment for SCD and TDT for patients 2 and older), and focus on serious and rare diseases with high unmet needs.
Official website: https://vrtx.com/
Last analyzed: August 30, 2026
This Business Profile is published by Optimly in the Optimly AI Brand Index, a public research dataset showing how AI systems describe brands, categories, and competitors. Optimly AI Visibility analyzes sampled buyer-intent responses, cited sources, and public brand information. The Brand Authority Index summarizes answer presence, narrative accuracy, and owned citations where sufficient evidence is available.
If this is your brand, you can claim this profile to verify its contents and correct what AI models say about you: Claim this profile